91在线激情在线观看,亚洲综合第一页,天天做天天爱天天综合网

芐硝唑

NMR下載 COA and HPLC MSDS下載
names：
Benznidazol
CAS號：
22994-85-0
MDL Number： MFCD00243089
MF(分子式)： C12H12N4O3 MW(分子量)： 260.25
EINECS: Reaxys Number:
Pubchem ID:31593 Brand:BIOFOUNT

芐硝唑(22994-85-0,Benznidazol)是硝基咪唑衍生物，通過干擾寄生蟲蛋白質的生物合成，影響細胞因子的產生并刺激宿主的吞噬作用而具有抗原生動物活性。芐硝唑是一種單羧酸酰胺，其通過將（2-硝基咪唑-1-基）乙酸的羧基與芐胺的芳族氨基縮合而獲得。

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
YZM000814-100mg	100mg	99.6%	￥ 2160.00	￥ 2160.00		2-3天	- +	￥ 0.00
YZM000814-25mg	25mg	99.6%	￥ 836.00	￥ 836.00		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	芐硝唑(22994-85-0,Benznidazol);芐噠唑
英文別名	Benznidazol(22994-85-0);Radanil;Benzonidazole
CAS號	22994-85-0
Inchi	InChI=1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)
InchiKey	CULUWZNBISUWAS-UHFFFAOYSA-N
分子式 Formula	C12H12N4O3
分子量 Molecular Weight	260.25
溶解度Solubility	生物體外In Vitro:DMSO溶解度160 mg/mL(614.79 mM;Need ultrasonic)
性狀	灰白色至淺黃色固體粉末
儲藏條件 Storage conditions	-20°C 3 years年 4°C 2 years年 / 溶液中:-80°C 6 months月 -20°C 1 month月

芐硝唑(22994-85-0,Benznidazol) 實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染

Benznidazol(22994-85-0) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:芐硝唑(22994-85-0,Benznidazol),芐硝唑試劑,芐硝唑的活性,芐硝唑的抑制劑,芐硝唑的純度,芐硝唑的圖譜,芐硝唑的生產,芐硝唑的含量,芐硝唑的雜質,芐硝唑的鹽酸鹽,芐硝唑的廠家,芐硝唑的合成,芐硝唑的MSDS,芐硝唑的注意事項

產品說明	芐硝唑(22994-85-0,Benznidazol)是硝基雜環(huán)化合物。芐硝唑表現(xiàn)出三種多態(tài)形式。
Introduction	Benznidazol(22994-85-0,芐硝唑) is a nitro heterocyclic compound. Benznidazole exhibits three polymorphic forms.
Application1	Benznidazole is associated with serum enzyme elevations during therapy in up to 10% of patients but has not linked to cases of clinically apparent acute liver injury.
Application2	Benznidazole is an orally available, broad spectrum antimicrobial agent used in the treatment of Chagas disease.
Application3

Benznidazol(22994-85-0,芐硝唑) is a nitro-heterocyclic compound. It is widely employed drug for the treatment of Chagas disease. It exhibits three polymorphic forms. It may be used as reference drug for the extraction of guaianolide from the aerial parts of Tanacetum parthenium.

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

象形圖
信號警告	Warning
GHS危險說明	Aggregated GHS information provided by 39 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H315 (97.44%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (97.44%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H335 (97.44%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
防范說明代碼	P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501 (The corresponding statement to each P-code can be found at the GHS Classification page.)

Cucurbit[7]uril as a possible nanocarrier for the antichagasic benznidazole: a computational approach(Journal of Inclusion Phenomena and Macrocyclic Chemistry,2020)

Study of benznidazole–cyclodextrin inclusion complexes, cytotoxicity and trypanocidal activity(Journal of Inclusion Phenomena and Macrocyclic Chemistry,2011)

Designing and monitoring microstructural properties of oligosaccharide/co-solvent ternary complex particles to improve benznidazole dissolution

Trypanosoma cruzi infection and benznidazole therapy independently stimulate oxidative status and structural pathological remodeling of the liver tissue in mice

Targeting ROS overgeneration by N-benzyl-2-nitro-1-imidazole-acetamide as a potential therapeutic reposition approach for cancer therapy

Identification of N-benzylacetamide as a major component of human plasmatic metabolic profiling of benznidazole
Abstract:Chagas disease is an endemic infection in Latin America with a high health impact. Caused by the parasite Trypanosoma cruzi, it has expanded to non-endemic regions such as North America and European countries via immigration of infected people. This infectious disease has been rising in the ranking of international health priorities due to the growing migration flows from endemic to non-endemic areas. Benznidazole (BZN), a nitroheterocyclic drug, is one of the two trypanocidal drugs currently in clinical use, associated with significant adverse drug reactions (ADRs). Mammalian metabolism of BNZ has been poorly studied, including the potential role of metabolites on both toxicity and anti-parasitic activity. High-resolution UPLC/MS/MS was used to analyze three plasma samples obtained from pediatric patients under BNZ treatment in steady state. Spectroscopic and structural criteria were applied to identify BNZ and accompanying substances from chromatographic signals. From all detected species, two can be undoubtedly associated with the BNZ and N-benzylacetamide molecules, the second one being a fragment of the parent drug (BZN). From the obtained results, two hypotheses could be formulated. The first one is to relate the presence of N-benzyl acetamide with the hepatic metabolism of BNZ. The second hypothesis has to do with the possible trypanocidal activity of this metabolite, as well as its role in the development of side effects, associated with the pharmacotherapy. Complementary studies should be carried out to determine the possible association of this metabolite with the BNZ treatment stages, patient’s clinical features, ADRs, and trypanocidal effectiveness.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開